Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States

BACKGROUND: Pembrolizumab, a programmed cell death-1 (PD-1) inhibitor, has recently gained prominence as a second-line treatment for recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC). This study compares the acceptance and different influencing factors of pembrolizumab in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Maobai, Han, Sijie, Zheng, Bin, Cai, Hongfu, Yang, Jing, Zhuang, Qian, Li, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858623/
https://www.ncbi.nlm.nih.gov/pubmed/31814756
http://dx.doi.org/10.2147/CMAR.S226243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858623/
https://www.ncbi.nlm.nih.gov/pubmed/31814756
http://dx.doi.org/10.2147/CMAR.S226243

Ejemplares similares